Moreover, CD4+ T-cell subtypes are dysregulated and can serve as a prognosis biomarker in acute coronary syndrome (ACS) patients who have undergone percutaneous coronary intervention (PCI). The gene discussed is CD4; the disease is acute coronary syndrome.